• Recently, Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy test as a companion diagnostic for a specific type of lung cancer, while several directors and insiders reported stock sales and equity award vestings.
• This combination of a major regulatory milestone and visible insider activity offers investors fresh information about the company’s product positioning and leadership incentives.
• We’ll examine how the FDA approval of Guardant360 CDx shapes Guardant Health’s investment narrative in light of its recent share price gains.

Capitalize on the AI infrastructure supercycle with our selection of the 49 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

What Is Guardant Health's Investment Narrative?

To own Guardant Health, you have to believe that liquid biopsies and blood-based cancer screening can become core tools in oncology and population health, and that Guardant can turn its growing test menu into a much larger, more profitable business over time. The recent FDA approval of Guardant360 CDx for HER2-mutant lung cancer fits this thesis neatly, reinforcing the company’s role in precision oncology and adding to an already crowded slate of potential catalysts across Shield, Reveal and Infinity partnerships. The quick share price reaction and clustered analyst upgrades suggest this approval is being treated as a meaningful near-term driver rather than a minor label tweak. At the same time, fresh insider selling around 52-week highs, ongoing losses and negative equity keep financing risk and execution risk front and center for shareholders.

However, investors also need to understand the financing and dilution risk sitting in the background. Guardant Health's shares have been on the rise but are still potentially undervalued by 12%. Find out what it's worth.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span roughly US$17 to US$162, underlining very different expectations. Set that against today’s elevated valuation and reliance on continued FDA, reimbursement and partnership momentum, and it becomes clear why you should compare several viewpoints before making up your mind.

Explore 6 other fair value estimates on Guardant Health - why the stock might be worth as much as 14% more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Guardant Health research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• Our free Guardant Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Guardant Health's overall financial health at a glance.

Interested In Other Possibilities?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• The future of work is here. Discover the 31 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Uncover the next big thing with 22 elite penny stocks that balance risk and reward.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.